Exam 3: HIV Flashcards
Stage 1: Acute infection
CD4: 500+
Manifestations: Flu like symptoms, chills, rash, anorexia, nausea, weight loss, weakness, fatigue, headache, sore throat, night sweats
1-4 weeks
Stage 2: Clinical latency
Prolonged and asymptomatic
Anti-HIV antibodies produced
CD4: 200-499
Stage 3: AIDS
Defining opportunistic conditions
CD4: less than 200
Expected findings: Chills, fever, sweats, swollen lymph glands, weakness, fatigue, weight loss
AIDS defining opportunistic conditions
Kaposis Sarcoma
Pneymocystic jirovecii pneumonia
Microbacterium TB
Wasting syndrome
Candidiasis
HIV transmission
Bodily fluids containing HIV or infected CD4 lymphocytes
Blood, seminal fluid, vaginal secretions, amniotic fluid, human milk
Most prenatal infections occur during delivery
Casual contact does not cause transmission
Laboratory test
CD4 T-Lymphocyte count: Serves as the major laboratory indicator of immune function and prophylaxis for opportunistic infections, strongest predictor of subsequent disease progression and survival
Stage 1: 500
Stage 2: 200-499
Stage 3: Below 200
HIV Viral Load: determines viral load before beginning treatment, can be repeated to monitor disease progression, identify compliance with treatment, and determine HIV medication resistance
HIV drug resistance testing: Guides changes in medication therapy when resistance occurs, useful with CD4 counts fall despite therapy
Goal of ART
Suppress HIV replication to a level below which drug-resistant mutations do not occur
Reduce HIV-associated morbidity and prolong the duration and quality of survival
Restore and preserve immunologic function
Maximally and durably suppress plasma HIV viral load
Prevent HIV transmission
Adverse effects of ART
Hepatotoxicity
Nephrotoxicity
Osteopenia
Increased risk of CV disease and MI
Lipodystrophy (fat redistribution syndrome)
Metabolic alterations
PrEP
One pill containing two HIV medications taken daily to reduce risk of sexual HIV acquisition in adults and adolescents age 12 and older
HIV status should be checked every 3 months
Goal: Reduce acquisition of HIV infection with its resulting morbidity, mortality, and cost to individuals and society